Matching of XEN®45 and PRESERFLO™ MicroShunt cases: Outcomes of a 3-year follow-up
Both XEN and PRESERFLO effectively reduce IOP and the need for glaucoma medication, with comparable surgical success rates after 3 years. PRESERFLO demonstrated a lower revision rate and reduced frequency of early postoperative hypotony. These findings support both implants as viable options for minimally invasive glaucoma surgery, with low risk profiles.
Authors
- Thomas A. Fuchsluger
- Tobias Brockmann (ORCID: https://orcid.org/0000-0001-6939-1159)
- Marcus Walckling (ORCID: https://orcid.org/0000-0001-7732-9507)
- Cemre Altas (ORCID: https://orcid.org/0009-0005-4384-1066)
- Anselm G. Jünemann
- Fabian Stelzle
Institutions
- Institut für Umwelttechnologien und Strahlenschutz (Germany) (DE)
- Universitätsklinikum Erlangen (DE)
- Ernst Abbe University of Applied Sciences Jena (DE)
- University of Rostock (DE)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1371/journal.pone.0335080
- Citations
- 3
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 5.12